Syndax Pharmaceuticals Inc (SNDX)
21.88
+0.22
(+1.02%)
USD |
NASDAQ |
May 15, 15:01
Syndax Pharmaceuticals Enterprise Value: 1.398B for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 1.398B |
| May 13, 2024 | 1.339B |
| May 10, 2024 | 1.405B |
| May 09, 2024 | 1.424B |
| May 08, 2024 | 1.459B |
| May 07, 2024 | 1.527B |
| May 06, 2024 | 1.469B |
| May 03, 2024 | 1.431B |
| May 02, 2024 | 1.415B |
| May 01, 2024 | 1.424B |
| April 30, 2024 | 1.352B |
| April 29, 2024 | 1.365B |
| April 26, 2024 | 1.347B |
| April 25, 2024 | 1.305B |
| April 24, 2024 | 1.324B |
| April 23, 2024 | 1.339B |
| April 22, 2024 | 1.338B |
| April 19, 2024 | 1.324B |
| April 18, 2024 | 1.298B |
| April 17, 2024 | 1.319B |
| April 16, 2024 | 1.365B |
| April 15, 2024 | 1.394B |
| April 12, 2024 | 1.403B |
| April 11, 2024 | 1.454B |
| April 10, 2024 | 1.427B |
| Date | Value |
|---|---|
| April 09, 2024 | 1.511B |
| April 08, 2024 | 1.495B |
| April 05, 2024 | 1.502B |
| April 04, 2024 | 1.479B |
| April 03, 2024 | 1.579B |
| April 02, 2024 | 1.536B |
| April 01, 2024 | 1.578B |
| March 28, 2024 | 1.445B |
| March 27, 2024 | 1.383B |
| March 26, 2024 | 1.244B |
| March 25, 2024 | 1.329B |
| March 22, 2024 | 1.341B |
| March 21, 2024 | 1.367B |
| March 20, 2024 | 1.379B |
| March 19, 2024 | 1.311B |
| March 18, 2024 | 1.285B |
| March 15, 2024 | 1.421B |
| March 14, 2024 | 1.347B |
| March 13, 2024 | 1.441B |
| March 12, 2024 | 1.450B |
| March 11, 2024 | 1.425B |
| March 08, 2024 | 1.510B |
| March 07, 2024 | 1.417B |
| March 06, 2024 | 1.440B |
| March 05, 2024 | 1.372B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
75.13M
Minimum
Oct 09 2019
1.579B
Maximum
Apr 03 2024
687.91M
Average
657.06M
Median
Enterprise Value Benchmarks
| Geron Corp | 1.822B |
| Verastem Inc | 285.35M |
| Karyopharm Therapeutics Inc | 150.85M |
| Crinetics Pharmaceuticals Inc | 2.993B |
| Arvinas Inc | 977.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -72.40M |
| Total Expenses (Quarterly) | 79.51M |
| EPS Diluted (Quarterly) | -0.85 |
| Earnings Yield | -14.72% |
| Operating Earnings Yield | 1.61% |
| Normalized Earnings Yield | 1.965 |